Aerie Pharmaceuticals Inc. (NASDAQ:AERI) was up 2.4% during trading on Tuesday . The company traded as high as $19.58 and last traded at $19.45, with a volume of 119,952 shares changing hands. The stock had previously closed at $18.99.

A number of equities research analysts recently commented on AERI shares. Zacks Investment Research lowered Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Needham & Company LLC reiterated a “buy” rating and issued a $45.00 target price on shares of Aerie Pharmaceuticals in a research report on Tuesday, August 23rd. Brean Capital reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, May 16th. Cantor Fitzgerald started coverage on Aerie Pharmaceuticals in a research report on Thursday, June 2nd. They issued a “buy” rating and a $44.00 target price on the stock. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Tuesday, May 3rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $42.50.

The company has a 50 day moving average of $18.18 and a 200-day moving average of $16.27. The company’s market cap is $541.66 million.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.02. Equities research analysts forecast that Aerie Pharmaceuticals Inc. will post ($2.74) earnings per share for the current year.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of the business’s stock in a transaction dated Friday, July 22nd. The shares were acquired at an average price of $17.50 per share, with a total value of $4,375,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.